MA29601B1 - Vaccin antipaludeen - Google Patents
Vaccin antipaludeenInfo
- Publication number
- MA29601B1 MA29601B1 MA30510A MA30510A MA29601B1 MA 29601 B1 MA29601 B1 MA 29601B1 MA 30510 A MA30510 A MA 30510A MA 30510 A MA30510 A MA 30510A MA 29601 B1 MA29601 B1 MA 29601B1
- Authority
- MA
- Morocco
- Prior art keywords
- antipaludeen
- vaccine
- derivative
- travelers
- saponin
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000224016 Plasmodium Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne, entre autres, un procédé destiné à la prophylaxie de l'infection par le paludisme chez les voyageurs qui se rendent dans des régions endémiques, comprenant l'administration de quantités adéquates d'une formulation contenant un antigène de Plasmodium ou un fragment immunogénique ou un dérivé de celui-ci et un adjuvant, comprenant un dérivé de lipide A et une saponine dans une formulation liposomique.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0513421.8A GB0513421D0 (en) | 2005-06-30 | 2005-06-30 | Vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29601B1 true MA29601B1 (fr) | 2008-07-01 |
Family
ID=34856445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30510A MA29601B1 (fr) | 2005-06-30 | 2007-12-26 | Vaccin antipaludeen |
Country Status (22)
Country | Link |
---|---|
US (1) | US9279006B2 (fr) |
EP (1) | EP1896060B1 (fr) |
JP (1) | JP5486802B2 (fr) |
KR (2) | KR20130111648A (fr) |
CN (1) | CN101208100A (fr) |
AR (1) | AR055069A1 (fr) |
AU (1) | AU2006265329B2 (fr) |
BR (1) | BRPI0613087A2 (fr) |
CA (1) | CA2613057C (fr) |
EA (1) | EA200702633A1 (fr) |
ES (1) | ES2529577T3 (fr) |
GB (1) | GB0513421D0 (fr) |
IL (1) | IL187769A0 (fr) |
MA (1) | MA29601B1 (fr) |
MX (1) | MX2007016240A (fr) |
NO (1) | NO20076200L (fr) |
NZ (1) | NZ564156A (fr) |
PE (1) | PE20070203A1 (fr) |
TW (1) | TW200800254A (fr) |
UA (1) | UA93508C2 (fr) |
WO (1) | WO2007003384A1 (fr) |
ZA (1) | ZA200710615B (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20080428A1 (es) | 2006-07-18 | 2008-05-15 | Glaxosmithkline Biolog Sa | Vacunas para la malaria |
US9717788B2 (en) | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
CN105106971A (zh) * | 2007-03-02 | 2015-12-02 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物及其在刺激免疫反应中的用途 |
BRPI0815199A2 (pt) * | 2007-08-13 | 2015-03-31 | Glaxosmithkline Biolog Sa | Uso de um antígeno derivado da proteína circunsporozóite de plasmodium falciparum |
CL2008003614A1 (es) * | 2007-12-06 | 2010-01-15 | Glaxosmithkline Biologicals Sa | Vector de adenovirus de simio deficiente de replicacion c7 que comprende la proteina cs de p. falciparum o un fragmento de la misma; composicion que lo contiene en combinacion con un antigeno de malaria y un co-adyuvante; util en el tratamiento o profilaxis de la malaria. |
BRPI0822098A2 (pt) * | 2007-12-21 | 2015-06-30 | Glaxosmithkline Biolog Sa | Componente para uma vacina contra malária, vacina para malária, processo para a preparação do componente, uso do componente, e, método de tratar um paciente suscetível às infecções por plasmodium |
TW200940087A (en) | 2007-12-24 | 2009-10-01 | Glaxosmithkline Biolog Sa | Vaccines for malaria |
GB0815872D0 (en) * | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
WO2011115684A2 (fr) | 2010-03-19 | 2011-09-22 | Massachusetts Institute Of Technology | Compositions de vésicules lipidiques et procédés pour les utiliser |
US9149432B2 (en) | 2010-03-19 | 2015-10-06 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
EP2566506B1 (fr) * | 2010-05-07 | 2016-07-06 | Virbac | Composition vaccinale destinee a la prevention ou au traitement des leishmanioses |
US9249191B2 (en) | 2012-02-16 | 2016-02-02 | Vlp Therapeutics, Llc | Virus like particle composition |
CN105431535A (zh) * | 2013-06-03 | 2016-03-23 | Vlp治疗有限责任公司 | 疟疾疫苗 |
US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
WO2015091734A1 (fr) * | 2013-12-20 | 2015-06-25 | Glaxosmithkline Biologicals S.A. | Nouveaux vaccins contre la malaria |
CN106104258B (zh) * | 2014-02-05 | 2019-11-29 | 莫纳什大学 | 快速检测疟疾的系统 |
JP6824154B2 (ja) | 2014-08-08 | 2021-02-03 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC | 修飾エンベロープタンパク質e3を含むウイルス様粒子 |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
CN106687590B (zh) | 2014-09-11 | 2021-08-03 | Vlp治疗公司 | 黄热病毒病毒样颗粒 |
WO2016184784A1 (fr) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Peptides comprenant le domaine de liaison des protéines de plasmodium falciparum (cbp1 et cbp2) à cx3cl1 de chimiokine |
US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
WO2018209265A1 (fr) * | 2017-05-11 | 2018-11-15 | Atreca, Inc. | Anticorps antipaludéens qui se lient à la protéine circumsporozoïte |
WO2020193520A1 (fr) | 2019-03-25 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Traitement de troubles de tauopathie par ciblage de nouvelles espèces tau |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) * | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) * | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) * | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
EP0071705B1 (fr) * | 1981-05-21 | 1989-11-23 | The Wellcome Foundation Limited | Antigène protozoaire |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
CA1331443C (fr) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Adjuvant a saponine |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
GB9002512D0 (en) | 1990-02-05 | 1990-04-04 | 3I Res Expl Ltd | Polypeptides and dna encoding same |
GB9012580D0 (en) | 1990-06-06 | 1990-07-25 | Univ Nijmegen | Novel protein |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5198535A (en) | 1991-01-10 | 1993-03-30 | The United States Of America As Represented By The Secretary Of The Navy | Protective malaria sporozoite surface protein immunogen and gene |
ATE177755T1 (de) * | 1991-11-16 | 1999-04-15 | Smithkline Beecham Biolog | Hybrides protein zwischen cs aus plasmodium und hbsag |
JP3723231B2 (ja) | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | アジュバント |
EP0671948B1 (fr) | 1992-06-25 | 1997-08-13 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Composition vaccinale contenant des adjuvants |
ES2109685T5 (es) | 1993-03-23 | 2005-09-01 | Smithkline Beecham Biologicals S.A. | Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado. |
WO1995012565A1 (fr) | 1993-11-01 | 1995-05-11 | E.I. Du Pont De Nemours And Company | Procede de production de trichlorotrifluoroethanes |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
DE69535036T3 (de) | 1994-07-15 | 2011-07-07 | The University of Iowa Research Foundation, IA | Immunomodulatorische oligonukleotide |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
GB9616351D0 (en) * | 1996-08-02 | 1996-09-11 | Smithkline Beecham Biolog | Vaccine composition |
AU4255397A (en) * | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
DE69733020T2 (de) | 1996-10-11 | 2006-02-16 | The Regents Of The University Of California, Oakland | Immunostimulierende oligonucleotidekonjugate |
ATE261322T1 (de) | 1997-03-29 | 2004-03-15 | Ji Hoon Park | Dauerinjektionsvorrichtung |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
CA2654522C (fr) | 1997-08-29 | 2014-01-28 | Antigenics Inc. | Compositions renfermant l'adjuvant qs-21 et du polysorbate ou de la cyclodextrine comme excipient |
AU1145699A (en) | 1997-09-05 | 1999-03-22 | Smithkline Beecham Biologicals (Sa) | Oil in water emulsions containing saponins |
WO2002077195A2 (fr) | 2001-03-26 | 2002-10-03 | Walter Reed Army Institute Of Research | Proteine ama-1 de plasmodium falciparum et ses applications |
BR0214350A (pt) | 2001-11-21 | 2005-05-10 | Univ Pennsylvania | Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso |
AU2002360429A1 (en) | 2001-11-26 | 2003-06-10 | Avigen, Inc. | Methods for producing stocks of recombinant aav virions |
JP5404990B2 (ja) | 2002-10-23 | 2014-02-05 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | マラリアに対するワクチン接種の方法 |
WO2004044167A2 (fr) | 2002-11-12 | 2004-05-27 | Walter Reed Army Institute Of Research | Expression, purification et utilisation d'un polypeptide d'antigene lsa-1 de plasmodium falciparum |
GB0420634D0 (en) | 2004-09-16 | 2004-10-20 | Glaxosmithkline Biolog Sa | Vaccines |
AU2005293572B2 (en) * | 2004-10-14 | 2011-08-04 | Crucell Holland B.V. | Malaria prime/boost vaccines |
EP1754717A1 (fr) * | 2005-08-19 | 2007-02-21 | Université de Lausanne | Peptides antigéniques et leurs utilisations |
-
2005
- 2005-06-30 GB GBGB0513421.8A patent/GB0513421D0/en not_active Ceased
-
2006
- 2006-06-28 AR ARP060102788A patent/AR055069A1/es not_active Application Discontinuation
- 2006-06-28 PE PE2006000756A patent/PE20070203A1/es not_active Application Discontinuation
- 2006-06-29 NZ NZ564156A patent/NZ564156A/en not_active IP Right Cessation
- 2006-06-29 KR KR1020137025375A patent/KR20130111648A/ko not_active Application Discontinuation
- 2006-06-29 EP EP06762331.4A patent/EP1896060B1/fr active Active
- 2006-06-29 TW TW095123690A patent/TW200800254A/zh unknown
- 2006-06-29 MX MX2007016240A patent/MX2007016240A/es active IP Right Grant
- 2006-06-29 EA EA200702633A patent/EA200702633A1/ru unknown
- 2006-06-29 CA CA2613057A patent/CA2613057C/fr not_active Expired - Fee Related
- 2006-06-29 UA UAA200713498A patent/UA93508C2/ru unknown
- 2006-06-29 CN CNA2006800231391A patent/CN101208100A/zh active Pending
- 2006-06-29 WO PCT/EP2006/006407 patent/WO2007003384A1/fr active Application Filing
- 2006-06-29 ES ES06762331.4T patent/ES2529577T3/es active Active
- 2006-06-29 JP JP2008518748A patent/JP5486802B2/ja not_active Expired - Fee Related
- 2006-06-29 KR KR1020087002486A patent/KR20080030640A/ko active Search and Examination
- 2006-06-29 BR BRPI0613087-9A patent/BRPI0613087A2/pt not_active IP Right Cessation
- 2006-06-29 AU AU2006265329A patent/AU2006265329B2/en not_active Ceased
- 2006-06-29 US US11/917,788 patent/US9279006B2/en not_active Expired - Fee Related
-
2007
- 2007-11-29 IL IL187769A patent/IL187769A0/en unknown
- 2007-12-03 NO NO20076200A patent/NO20076200L/no not_active Application Discontinuation
- 2007-12-05 ZA ZA200710615A patent/ZA200710615B/xx unknown
- 2007-12-26 MA MA30510A patent/MA29601B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EA200702633A1 (ru) | 2008-06-30 |
ES2529577T3 (es) | 2015-02-23 |
CN101208100A (zh) | 2008-06-25 |
AU2006265329A1 (en) | 2007-01-11 |
ZA200710615B (en) | 2009-02-25 |
BRPI0613087A2 (pt) | 2012-10-09 |
EP1896060B1 (fr) | 2014-12-03 |
WO2007003384A1 (fr) | 2007-01-11 |
NZ564156A (en) | 2011-08-26 |
UA93508C2 (en) | 2011-02-25 |
KR20130111648A (ko) | 2013-10-10 |
JP2008544969A (ja) | 2008-12-11 |
IL187769A0 (en) | 2008-08-07 |
NO20076200L (no) | 2008-03-27 |
GB0513421D0 (en) | 2005-08-03 |
PE20070203A1 (es) | 2007-03-28 |
TW200800254A (en) | 2008-01-01 |
US9279006B2 (en) | 2016-03-08 |
US20080317787A1 (en) | 2008-12-25 |
KR20080030640A (ko) | 2008-04-04 |
CA2613057C (fr) | 2016-02-02 |
JP5486802B2 (ja) | 2014-05-07 |
AR055069A1 (es) | 2007-08-01 |
EP1896060A1 (fr) | 2008-03-12 |
AU2006265329B2 (en) | 2012-12-20 |
MX2007016240A (es) | 2008-03-07 |
CA2613057A1 (fr) | 2007-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29601B1 (fr) | Vaccin antipaludeen | |
RU2349342C2 (ru) | Менингококковые вакцины для введения через слизистую оболочку | |
ES2331952T3 (es) | Fraccion de quil a con baja toxicidad y su uso. | |
RU2378009C2 (ru) | Иммунизация против менингококков серогруппы y с помощью белков | |
BRPI0010612B8 (pt) | vacinas | |
WO2005097211A3 (fr) | Compositions adjuvantes ameliorant la reponse immunitaire a des vaccins et methodes d'utilisation | |
MA30624B1 (fr) | Vaccin anti-grippal | |
AR051023A1 (es) | Vacunas que contienen antigeno de plasmodium | |
HUP0400445A2 (hu) | Új vakcinakészítmények | |
HUP0303720A2 (hu) | Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény | |
CY1111553T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου γριπης για ενδοδερμικη χορηγηση | |
CO5680456A2 (es) | Composiciones de vacunas que comprenden lipooligosacaridos del inmunotipo l2 y/o l3 a partir de lgtb-neisseria minigitidis | |
HUP0402067A2 (hu) | Oltóanyagok | |
DK1326636T3 (da) | Vaccinesammensætning | |
BR0212999A (pt) | novas composições imunogênicas para a prevenção e tratamento de doença meningocócica | |
MA29715B1 (fr) | Utilisation d'un virus de la grippe et d'un adjuvant de type emulsion huile dans l'eau pour induire une cellule t cd-4 et/ou ameliorer la reponse de la cellule a memoire b | |
ATE463261T1 (de) | Meningokokken-konjugat-impfung | |
BR9507400A (pt) | Composições imunogénicas de polissacaridio streptococal grupo a e processos | |
Abhyankar et al. | Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica | |
DK1383752T3 (da) | Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser | |
DE60331412D1 (de) | Hiv-vakzine und anwendungsverfahren | |
WO2005074460A3 (fr) | Procedes pour ameliorer la reponse immunitaire dans une partie intradermique et composes utilises dans ces procedes | |
MA28035A1 (fr) | Vaccin | |
WO2003101482A3 (fr) | Formulations de vaccins associes a des liposomes, destinees a des poissons a nageoires | |
Lea et al. | Virosomal Hepatitis A Vaccine (Strain RG-SB) A Preliminary Review of its Immunogenicity, Protective Efficacy and Tolerability in At-Risk Populations |